Actavis Group hf. - Strategic SWOT Analysis Review
GlobalData
February 6, 2012 27 Pages - SKU: GBDT6797529
|
|
Actavis Group hf. - Strategic SWOT Analysis Review
Summary
Actavis Company Hf. (Actavis), formerly Pharmaco Hf., is one of the leading pharmaceutical company engaged in the development, manufacturing and selling of first-class generic pharmaceuticals. The company’s product portfolio comprises 830 marketed products across various therapeutic areas and hospital applications and 330 products in pipeline and pending registrations. The primary customers of the company include wholesalers, medical practitioners, pharmacies, health authorities, and pharmaceutical manufacturers. The company has operations in more than 40 countries divided in three regions namely, North America, Europe and Asia Pacific. Actavis is headquartered at Zug, Switzerland.
The company focuses on establishing itself as the leading player in the generic pharmaceutical industry in the international arena. Actavis is actively pursuing this strategy by expanding into emerging countries by launch of new products in the in-demand categories. This is indicated by the company’s intent to enter the Turkish Oncology Market. The company also concentrates on gaining the first mover advantage for the pharmaceuticals going off-patent in the near future. This can be seen from the launch of Valsartan and Valsartan HCT and Levetiracetam Extended-Release tablets in the recent past as well as 180-day market exclusivity by Food and Drug Administration (FDA) for selling generic versions of Clobex Shampoo and Clobex Topical Lotion.
Actavis Group hf. Key Recent Developments
Oct 14, 2011: Actavis Donates €2m Worth Of Medicines To Libya
Sep 30, 2011: Actavis Launches Olanzapine Tablets In 11 Additional Markets
Sep 28, 2011: Actavis Steps Out Of Polfa Warszawa Bidding Process And Announces Aggressive Sales Strategy For Poland
Aug 26, 2011: Actavis Launches Letrozole In Nine European Markets
Jul 07, 2011: Actavis Launches Levofloxacin In Eight European Countries
GlobalData’s Actavis Group hf. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - GlobalData’s summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
Note: Some sections may be missing if data is unavailable for the company.
Reasons to Buy- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
|
Section 1 - About the Company - Actavis Group hf. - Key Facts
- Actavis Group hf. - Key Employees
- Actavis Group hf. - Key Employee Biographies
- Actavis Group hf. - Major Products and Services
- Actavis Group hf. - History
- Actavis Group hf. - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 - Company Analysis
- Actavis Group hf. - Business Description
- Actavis Group hf. - Corporate Strategy
- Actavis Group hf. - SWOT Analysis
- SWOT Analysis - Overview
- Actavis Group hf. - Strengths
- Strength - Strong Product Portfolio
- Strength - Widespread Research and Manufacturing Facilities
- Strength - Geographic Presence
- Actavis Group hf. - Weaknesses
- Weakness - Product Recall
- Actavis Group hf. - Opportunities
- Opportunity - Biotech Focus
- Opportunity - Emerging Markets
- Opportunity - New Product Launches
- Opportunity - Inorganic Growth Strategies
- Actavis Group hf. - Threats
- Threat - Stringent Government Regulations
- Threat - Growing Parallel Trade
- Threat - Cost Containment Pressures
- Threat - Intense Competition
- Actavis Group hf. - Key Competitors
- Section 3 - Company’s Lifesciences Financial Deals and Alliances
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
- Actavis Group hf., Recent Deals Summary
- Section 4 - Company’s Recent Developments
- Actavis Group hf., Recent Developments
- Oct 14, 2011: Actavis Donates €2m Worth Of Medicines To Libya
- Sep 30, 2011: Actavis Launches Olanzapine Tablets In 11 Additional Markets
- Sep 28, 2011: Actavis Steps Out Of Polfa Warszawa Bidding Process And Announces Aggressive Sales Strategy For Poland
- Aug 26, 2011: Actavis Launches Letrozole In Nine European Markets
- Jul 07, 2011: Actavis Launches Repaglinide Tablets In UK, Sweden And Hungary
- Jul 07, 2011: Actavis Launches Levofloxacin In Eight European Countries
- May 05, 2011: Actavis Launches Olanzapine In Four European Countries
- Apr 20, 2011: Actavis Produces 10 Million Tablets For Japan In Record Time
- Apr 14, 2011: CHMP Adopts Positive Opinion For Medicinal Product Rivastigmine Actavis In Alzheimer’s Dementia
- Feb 15, 2011: Actavis Launches Anastrozole In Seven Major European Markets
- Section 5 - Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Actavis Group hf., Key Facts
- Actavis Group hf., Key Employees
- Actavis Group hf., Key Employee Biographies
- Actavis Group hf., Major Products and Services
- Actavis Group hf., History
- Actavis Group hf., Other Locations
- Actavis Group hf., Subsidiaries
- Actavis Group hf., Key Competitors
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
- Actavis Group hf., Recent Deals Summary
- List of Figures
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
- Actavis Group hf., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012
Share this report
Other tasks Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
